Influenza
Conditions
Keywords
Influenza, Vaccine, Immunogenicity
Brief summary
The purpose of this study is to evaluate the antibody response to each of the three influenza vaccine strains included in the seasonal flu vaccine(AdimFlu-S), as measured by hemagglutination inhibition (HAI) at 4 weeks after two doses of study vaccine, 4 weeks apart, in infants between 6 and 12 months of age.
Interventions
BIOLOGICALAdimFlu-S
0.25mL per injection 2 injections at 4 weeks apart
Sponsors
Adimmune Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Months to 1 Years
Healthy volunteers
Yes
Inclusion criteria
* Boys or girls and aged \>= 6 months old to \<= 12 months old on the day of first vaccination; * Subject's parent(s) or legal guardian(s) must be willing to comply with planned study procedures and be available for all study visits; * Subject must be in good physical health on the basis of medical history, physical examination; * Subject's parent(s) or legal guardian(s) must read and signed the study-specific informed consent prior to initiation of any study procedure.
Exclusion criteria
* Subjects had received influenza vaccine; * History of hypersensitivity to eggs or egg protein or similar pharmacological effects to study medication; * Personal or family history of Guillain- Barre' Syndrome; * An acute febrile illness within 1 week prior to vaccination; * Current upper respiratory illness (URI), including the common cold or nasal congestion within 72 hours; * Subjects with influenza-like illness as defined by the presence of fever (temperature \>= 38'C) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough;Treatment with an investigational drug or device, or participation in a clinical study, within 3 months before consent; * Immunodeficiency, immunosuppressive or significant chronic illness not suitable for inactivated influenza vaccination; * History of wheezing or bronchodilator use within 3 months prior to study vaccine; * Receipt of live virus vaccine within 1 month prior to study vaccine or expected receipt vaccination before the last blood sampling for immunogenicity evaluation; * Receipt of any inactivated vaccine within 2 weeks prior to study vaccination or expected receipt vaccination before the last blood sampling for immunogenicity evaluation; * Receipt of any blood products, including immunoglobulin in the prior 3 months; * Underlying condition in the investigators' opinion may interfere with evaluation of the vaccine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HA antibody titers will be determined using the WHO HAI reference technique. | Serum samples will be obtained prior to vaccination (baseline), and 4 weeks after each vaccination. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The secondary objective is to evaluate the safety and tolerability profiles including the presence or absence of the pre-specified reactogenicity events and other serious/non-serious adverse events of the AdimFlu-S manufactured by Adimmune Corporation. | (4 weeks after two doses of study vaccine, 4 weeks apart), Physical examination will be performed at each visit. Reactogenicity will be recorded for 7 days after each vaccination. | Safety data will consist of reactogenicity, serious and non-serious adverse events. Reactogenicity events are pre-specified adverse events systematically recorded for 7 days after each vaccination. The events included fever (≥38.0°C), runny nose or nasal congestion, cough, sore throat, muscle aches, headache, vomiting, nausea and malaise. Furthermore, the local (injection site) reactions were also evaluated, including soreness/pain, swelling, redness, ecchymosis and limitation of arm motion. |
Countries
Taiwan
Outcome results
None listed